CA2335112A1 - Combinaisons therapeutiques pour la fragilite musculo-squelettique - Google Patents
Combinaisons therapeutiques pour la fragilite musculo-squelettique Download PDFInfo
- Publication number
- CA2335112A1 CA2335112A1 CA002335112A CA2335112A CA2335112A1 CA 2335112 A1 CA2335112 A1 CA 2335112A1 CA 002335112 A CA002335112 A CA 002335112A CA 2335112 A CA2335112 A CA 2335112A CA 2335112 A1 CA2335112 A1 CA 2335112A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- oxo
- ethyl
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Cette invention concerne des compositions et des méthodes de combinaisons pharmaceutiques comprenant (-)-cis-6-phényl-5-(4-(2-pyrrolidin-1-yl-éthoxy)-phényl)-5,6,7,8-tétrahydronaphtalène-2-ol ou un sel acceptable sur le plan pharmaceutique de celui-ci et 2-amino-N-(1(R)-(2,4-difluoro-benzyloxyméthyl)-2-oxo-2-(3-oxo-3a(R)-pyridin-2-ylméthyl)-2-(2,2,2-trifluoro-éthyl)-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-éthyl)-2-méthyl-propionamide ou un sel acceptable sur le plan pharmaceutique, et des procédés d'utilisation de ces compositions ainsi que des kits contenant lesdites compositions. Les compositions sont utiles pour traiter la fragilité musculo-squelettique, notamment l'ostéoporose, les fractures ostéoporotiques, la faible masse osseuse, la fragilité et la faible masse musculaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 | |
| US60/089,424 | 1998-06-16 | ||
| PCT/IB1999/000796 WO1999065488A1 (fr) | 1998-06-16 | 1999-05-03 | Combinaisons therapeutiques de modulateurs (selectifs) des recepteurs des oestrogenes (serm) et de secretagogues d'hormones de croissance (ghs) pour traiter la fragilite musculo-squelettique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2335112A1 true CA2335112A1 (fr) | 1999-12-23 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002335112A Abandoned CA2335112A1 (fr) | 1998-06-16 | 1999-05-03 | Combinaisons therapeutiques pour la fragilite musculo-squelettique |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (fr) |
| JP (1) | JP2002518328A (fr) |
| KR (1) | KR20010052817A (fr) |
| CN (1) | CN1305378A (fr) |
| AP (1) | AP9901581A0 (fr) |
| AR (1) | AR018868A1 (fr) |
| AU (1) | AU3342099A (fr) |
| BG (1) | BG105128A (fr) |
| BR (1) | BR9911357A (fr) |
| CA (1) | CA2335112A1 (fr) |
| CO (1) | CO5070586A1 (fr) |
| EA (1) | EA200001189A1 (fr) |
| GT (1) | GT199900083A (fr) |
| HR (1) | HRP20000857A2 (fr) |
| HU (1) | HUP0102395A2 (fr) |
| ID (1) | ID26726A (fr) |
| IL (1) | IL139587A0 (fr) |
| IS (1) | IS5727A (fr) |
| MA (1) | MA26648A1 (fr) |
| NO (1) | NO20006381D0 (fr) |
| OA (1) | OA11569A (fr) |
| PA (1) | PA8472101A1 (fr) |
| PE (1) | PE20000633A1 (fr) |
| PL (1) | PL345064A1 (fr) |
| SK (1) | SK18902000A3 (fr) |
| TN (1) | TNSN99118A1 (fr) |
| UY (1) | UY25557A1 (fr) |
| WO (1) | WO1999065488A1 (fr) |
| ZA (1) | ZA993973B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (fr) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Agonistes/antagonistes de l'estrogène |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| ES2319785T3 (es) * | 2001-11-29 | 2009-05-12 | Gtx, Inc. | Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos. |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| EA200901077A1 (ru) | 2007-02-09 | 2010-04-30 | Транзим Фарма, Инк. | Макроциклические модуляторы грелинового рецептора и их применение |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-05-03 IL IL13958799A patent/IL139587A0/xx unknown
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 CA CA002335112A patent/CA2335112A1/fr not_active Abandoned
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/ja active Pending
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/ko not_active Application Discontinuation
- 1999-05-03 PL PL99345064A patent/PL345064A1/xx unknown
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/sk unknown
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/hu unknown
- 1999-05-03 ID IDW20002604A patent/ID26726A/id unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/pt not_active Application Discontinuation
- 1999-05-03 CN CN99807381A patent/CN1305378A/zh active Pending
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/fr not_active Application Discontinuation
- 1999-05-03 EA EA200001189A patent/EA200001189A1/ru unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 EP EP99914723A patent/EP1085867A1/fr not_active Withdrawn
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/es unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/es not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/es not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/es unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/fr unknown
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/xx unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/es not_active Application Discontinuation
- 1999-06-15 MA MA25622A patent/MA26648A1/fr unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/es unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/is unknown
- 2000-12-14 HR HR20000857A patent/HRP20000857A2/hr not_active Application Discontinuation
- 2000-12-14 NO NO20006381A patent/NO20006381D0/no not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY25557A1 (es) | 2001-01-31 |
| PA8472101A1 (es) | 2000-09-29 |
| ID26726A (id) | 2001-02-01 |
| EP1085867A1 (fr) | 2001-03-28 |
| IS5727A (is) | 2000-11-24 |
| WO1999065488A1 (fr) | 1999-12-23 |
| PL345064A1 (en) | 2001-11-19 |
| TNSN99118A1 (fr) | 2005-11-10 |
| EA200001189A1 (ru) | 2001-06-25 |
| JP2002518328A (ja) | 2002-06-25 |
| PE20000633A1 (es) | 2000-07-26 |
| BG105128A (en) | 2001-11-30 |
| BR9911357A (pt) | 2001-03-13 |
| HUP0102395A2 (hu) | 2001-11-28 |
| KR20010052817A (ko) | 2001-06-25 |
| AP9901581A0 (en) | 1999-06-30 |
| IL139587A0 (en) | 2002-02-10 |
| HRP20000857A2 (en) | 2001-10-31 |
| NO20006381L (no) | 2000-12-14 |
| OA11569A (en) | 2004-07-01 |
| CN1305378A (zh) | 2001-07-25 |
| MA26648A1 (fr) | 2004-12-20 |
| AU3342099A (en) | 2000-01-05 |
| AR018868A1 (es) | 2001-12-12 |
| NO20006381D0 (no) | 2000-12-14 |
| ZA993973B (en) | 2000-12-15 |
| SK18902000A3 (sk) | 2001-12-03 |
| CO5070586A1 (es) | 2001-08-28 |
| GT199900083A (es) | 2000-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1179A (en) | Combination therapy for osteoporosis. | |
| US7632813B2 (en) | Bone densifying agent characterized by use of cathepsin K inhibitor with PTH | |
| PT1414486E (pt) | Utilizaão de glp-2 em combinaão com outro agente teraputico em perturbaães ësseas | |
| CN104800208A (zh) | 选择性s1p1受体激动剂的给药方案 | |
| US20040122062A1 (en) | Use of growth hormone secretagogues for treatment of physical performance decline | |
| CA2335112A1 (fr) | Combinaisons therapeutiques pour la fragilite musculo-squelettique | |
| OA11566A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone. | |
| AU4054799A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| US20020002137A1 (en) | Combination of growth hormone secretagogues and antidepressants | |
| AU7613001A (en) | Use of growth hormone secretagogues in conjunction with physical exercise | |
| MXPA00012628A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| US6284773B1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2 | |
| JP2002293743A (ja) | 食欲を刺激するかまたは増進させるための成長ホルモン分泌促進物質の使用 | |
| CZ20004680A3 (cs) | Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility | |
| MXPA00012727A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| US20030199514A1 (en) | Methods for improving efficacy of treatment with growth hormone secretagogues | |
| CZ20004679A3 (cs) | Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility | |
| US6555531B1 (en) | Weight promoting composition, method, and product | |
| MXPA00012728A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| MXPA99005564A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |